被称为"AI慢病管理第一股"的方舟健客(6086.HK)盘初曾直线拉升涨至9%，现报4.22港元，总市值56.6亿港元。消息上，方 舟健客日前发布业绩显示，2025年上半年收入14.94亿，同比增长12.9%；净利润实现扭亏为盈，达1250万元；经调整净利润 再创新高，达1760万元，同比增长16.8%。 信达证券研报指出，方舟健客25H1归母净利润扭亏为盈，期待25H2业绩及AI布局双突破，作为中国领先的线上慢病管理平 台，公司月活用户超1100万名且复购率达85%。截至2025H1，公司平台的注册用户达到5280万名，截至2025年6月30日的十 二个月平均月活跃用户为1190万名。同时，公司付费用户的重复购买率达85.4%。此外，公司仍特别专注于诸如减重、代谢 类、传染类等专科领域。 责任编辑：栎树 该行续指，公司部署了"AI导诊智能体"协助患者选择医生及适配科室，并推出"AI医生助理"为医生提供诊疗支持。同时， 公司亦升级了"AI客服助理"，以更好地支持患者全程的用药管理。公司构建了一个促进医生效率持续提升、对患者进行全 生命周期管理的创新业务模式。 ...

证券研究报告 公司研究 [Table_ReportType] 公司点评报告 上次评级 点评： [Table_Author] 唐爱金 医药行业首席分析师 执业编号：S1500523080002 邮 箱：tangaijin@cindasc.com 贺鑫 医药行业联席首席分析师 执业编号：S1500524120003 邮 箱：hexin1@cindasc.com 章钟涛 医药行业分析师 执业编号：S1500524030003 邮 箱：zhangzhongtao@cindasc.com 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦 B座 邮编：100031 核25H1 归母净利润扭亏为盈，期待 25H2 业绩及 AI 布局双突破 [Table_ReportDate] 2025 年 09 月 03 日 [Table_S 事件：公司发布 ummary] 2025 年中期业绩公告。2025H1 公司收入约为 14.94 亿元 （同比+12.91%），经调整净利润约 0.18 亿元（同比+16.8%），归母净利润 约 0.12 亿元（同比扭亏为盈）。 [T ...

Group 1 - The core viewpoint of the news is that Ark Health (06086) has shown significant financial improvement, with a notable increase in revenue and profitability in the first half of 2025 [1][2] - In the first half of 2025, the company recorded total revenue of 1.494 billion, representing a year-on-year growth of 12.9% [1] - The company achieved a net profit of 12.5 million, marking a turnaround from previous losses, while adjusted net profit reached a record high of 17.6 million, up 16.8% year-on-year [1] - The online retail pharmacy service revenue was 864 million, showing a substantial increase of 28.2% year-on-year [1] - The comprehensive medical service business revenue reached 357 million, reflecting a year-on-year growth of 11.4% [1] Group 2 - The company has upgraded its technology to "AI+H2H" (AI+Hospital To Home), focusing on creating a comprehensive AI application matrix covering user services, supply chain, and content production [2] - The "familiar doctor-patient" model is a cornerstone of the company's "AI+H2H" ecosystem, emphasizing long-term relationships over one-time consultations, leading to higher user loyalty, activity, and willingness to pay compared to industry averages [2] - Citigroup has initiated coverage of Ark Health with a "Buy" rating and a target price of 8.5 HKD, recognizing the growth certainty brought by its high-stickiness ecosystem [2]